Company intelligence / Profile preview

PROTEIMAX BIO TECHNOLOGY ISRAEL LTD

Rehovot, Israel

Ownership: Private
Development stage: Other

Overview

Company has discovered 54 naturally occurring peptides that modulate cannabinoid receptors, with lead compound Pep19 showing potential for fat metabolism and obesity management. Pep19 has received GRAS certification and is being commercialized as a food additive.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Peptides
Industry: Non-Drug Biotech

Partnerships

NutroslimSanval EnterpriseBINANational Animal Supplement Council

Beyond the preview

Go deeper on PROTEIMAX BIO TECHNOLOGY ISRAEL LTD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROTEIMAX BIO TECHNOLOGY ISRAEL LTD.

Explore the full profile